Literature DB >> 25391442

[Use of botulinum toxin type A in non-neurogenic overactive bladder. Recommendations of the Working Group Urological Functional Diagnostics and Urology in Women].

R M Bauer1, C Seif, T Bschleipfer, A Reitz, D Schultz-Lampel.   

Abstract

The use of botulinum toxin for the treatment of neurogenic detrusor overactivity was first described in 2000 and thereafter botulinum toxin has also been used in non-neurogenic overactive bladder. In current guidelines intravesical injection of onabotulinumtoxin A in refractory patients is recommended. Our aim is to provide some clinically relevant recommendations from the Working Group Urologische Funktionsdiagnostik und Urologie der Frau for diagnostics and treatment with onabotulinumtoxin A of patients with non-neurogenic overactive bladder.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25391442     DOI: 10.1007/s00120-014-3658-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  8 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.

Authors:  I Milsom; P Abrams; L Cardozo; R G Roberts; J Thüroff; A J Wein
Journal:  BJU Int       Date:  2001-06       Impact factor: 5.588

3.  OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Authors:  Victor W Nitti; Roger Dmochowski; Sender Herschorn; Peter Sand; Catherine Thompson; Christopher Nardo; Xiaohong Yan; Cornelia Haag-Molkenteller
Journal:  J Urol       Date:  2012-12-14       Impact factor: 7.450

Review 4.  An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.

Authors:  Bernard T Haylen; Dirk de Ridder; Robert M Freeman; Steven E Swift; Bary Berghmans; Joseph Lee; Ash Monga; Eckhard Petri; Diaa E Rizk; Peter K Sand; Gabriel N Schaer
Journal:  Neurourol Urodyn       Date:  2010       Impact factor: 2.696

Review 5.  The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

Authors:  Christopher R Chapple; Vik Khullar; Zahava Gabriel; Dominic Muston; Caty Ebel Bitoun; David Weinstein
Journal:  Eur Urol       Date:  2008-06-20       Impact factor: 20.096

6.  EAU guidelines on assessment and nonsurgical management of urinary incontinence.

Authors:  Malcolm G Lucas; Ruud J L Bosch; Fiona C Burkhard; Francisco Cruz; Thomas B Madden; Arjun K Nambiar; Andreas Neisius; Dirk J M K de Ridder; Andrea Tubaro; William H Turner; Robert S Pickard
Journal:  Eur Urol       Date:  2012-08-31       Impact factor: 20.096

7.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

8.  Patient-reported reasons for discontinuing overactive bladder medication.

Authors:  Joshua S Benner; Michael B Nichol; Eric S Rovner; Zhanna Jumadilova; Jose Alvir; Mohamed Hussein; Kristina Fanning; Jeffrey N Trocio; Linda Brubaker
Journal:  BJU Int       Date:  2009-11-12       Impact factor: 5.588

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.